Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 9031 results

  1. Ruxolitinib for treating moderate atopic dermatitis ID6602

    In development Reference number: GID-TA11809 Expected publication date: TBC

  2. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care

    Awaiting development Reference number: GID-HTG10850 Expected publication date: TBC

  3. Vertebral body tethering for idiopathic scoliosis in children and young people

    Awaiting development Reference number: GID-HTG10657 Expected publication date: TBC

  4. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

  5. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

  6. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

  7. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

  8. Oesophageal String Test

    Topic prioritisation

  9. High intensity focused electromagnetic (HIFEM) energy to target the pelvic floor muscles

    Topic prioritisation

  10. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

  11. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

  12. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

  13. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

  14. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date:  16 February 2027

  15. Aprocitentan for treating resistant hypertension [ID6681]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC